Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Is there a new trend in the journal world: publication of interim analysis (IA) results? The NEJM recently published two articles back to back, both highlighting 9 month ‘interim’ data from Phase 3 pivotal trials in IgAN. The primary efficacy endpoint used in either study was UPCR at 9 months, Continue reading IgAN Therapeutics – The Race is On
Today we discuss the group of BAFF/APRIL inhibitors, specifically the three TACI mAb constructs that are currently in development. They were tested in a broad gamut of B-cell indications but failed to show efficacy in many. So far, consistent clinical success has been seen only in IgA nephropathy (IgAN), with Continue reading BAFF / APRIL Inhibitors Homing in on IgAN